Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares fell 2% in ...

Goldman Sachs trims its staff, cutting what it deems to be the underperformers. This year, VPs stand to be big targets, BI ...

Pharmaceutical giant Moderna Inc. (NASDAQ:MRNA) lost 7.28 percent of its value on Monday to end the day at $36.55 apiece as investors continued to sell off positions following Goldman Sachs ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Goldman Sachs Asset Management is launching its first biodiversity fund for bond investors, in a move it says provides a new product to a market that’s so far been dominated by other asset classes.